eligibility_summary
Adults (≥18) with marginal zone lymphoma (incl. indolent B‑cell unclassifiable), stage II–IV, relapsed/refractory after ≥1 anti‑CD20–containing therapy, ECOG ≤2 (≤3 if lymphoma‑related), need systemic therapy per GELF, measurable disease or spleen/EMZL exceptions, adequate organ function. Exclude CNS lymphoma, recent therapy, active HBV/HCV/HIV or serious infection, immunosuppression, strong CYP3A inhibitors/inducers, major cardiac/ECG disease, bleeding diathesis, stroke/ICH ≤6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm study in relapsed/refractory marginal zone lymphoma evaluates mosunetuzumab plus zanubrutinib. Mosunetuzumab: a bispecific monoclonal antibody (IgG) that binds CD20 on B cells and CD3 on T cells, redirecting/activating T cells to kill CD20+ malignant B cells. Zanubrutinib: a second‑generation covalent small‑molecule BTK inhibitor that blocks B‑cell receptor (BCR) signaling, reducing downstream NF‑kB/ERK activation and B‑cell proliferation/survival. Targeted cells/pathways: CD20+ MZL B cells and CD3+ T cells (via T‑cell engagement), and the BTK/BCR pathway in malignant B cells. Rationale: combine T‑cell–mediated cytotoxicity with suppression of B‑cell survival signaling to enhance responses in R/R MZL.